PT-141

Hormonal Approved · US Human trials

Also called Bremelanotide, Vyleesi

A ring-shaped peptide derived from Melanotan-2. It activates melanocortin receptors in the brain, mainly MC4R, and increases sexual desire through the nervous system rather than through blood flow. Nausea and brief rises in blood pressure are the main side effects.

Evidence at a glance

Evidence: Human trials — Studied in people
Status: An approved medicine in US
Dosing: A dose has been tested in humans

Approved for premenopausal women with HSDD. Nausea affects about 40%, and it transiently raises blood pressure.

What studies report

Meaningful increase in sexual desire and satisfying events in phase 3 trials
Works through the brain rather than blood flow, so it suits people PDE5 drugs do not

How it works

Acts centrally on melanocortin receptors in the brain rather than on blood flow, which is why it works where PDE5 drugs do not.

Binds a receptor on the cell surface and signals inward

Where it acts

Pituitary gland

The library groups this compound under Hormonal. The diagram shows that target, not every tissue it reaches.

Illustrated

Small deep brain hypothalamic region within a translucent coronal brain section.

AI-generated subject illustration; not a depiction of the compound or evidence of its effects.

Why people take it

Libido and sexual desireSexual dysfunctionErectile functionSexual desire and arousalWorks via the brain rather than blood flow

Reasons people seek it out — not a list of proven effects.

In practice Off-label

Used situationally ahead of intimacy rather than on a schedule
Users commonly reduce the amount to manage nausea, which is the main complaint
Sometimes combined with PDE5 drugs, since it works on desire rather than blood flow

Reported real-world use, not evidence and not a recommendation.

Dosing

What was tested Evidence

1.75 mg, subcutaneous, as needed before activityPhase 3 (RECONNECT) in premenopausal women with HSDD→ Significant increase in desire and satisfying events

What people report using Not evidence

Taken situationally, 45 minutes to a few hours ahead
Amounts commonly reduced to manage nausea, which affects about 40%

Reported for reference, not as instruction. Nothing here is a recommendation to take anything, and most of these compounds are not approved for human use.

Status: FDA-approved (Vyleesi, 2019) for low sexual desire in premenopausal women.

Route: Subcutaneous injection (the approved product is an auto-injector); also sold as a ready-made intranasal spray
Sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
Formula: C50H68N14O10
Molecular weight: 1025.2 g/mol
CAS: 189691-06-3
Available as: 10 mg

View on PubChem →

Search PubMed for PT-141 → We link a live search rather than a fixed citation list, so it stays current and nothing here is a reference we have not checked.

Educational information only. Nothing here is medical advice, a dosing protocol, or a recommendation to use any compound. Most entries describe substances not approved for human use. Talk to a licensed clinician before acting on anything you read here. How to read these entries.